X

Category: R&D

2022 05 25

R&D

Scandinavian Biopharma

Scandinavian Biopharma extends its agreement with USAMMDA and obtains additional financial support

In 2020, Scandinavian Biopharma entered into an agreement with the United States Army Medical Materiel Development Activity (USAMMDA) to fund manufacturing and development activities for its ETEC diarrhoea vaccine, ETVAX®. The agreement has now been extended, providing additional financial support. The objective of USAMMDA’s financial support is to accelerate the development and approval of the […]

2021 11 19

R&D

Scandinavian Biopharma

An improved formulation of Scandinavian Bioharmas ETEC vaccine candidate is currently being tested in an immunogenicity bridging study

An improved user-friendly formulation of the world’s most advanced ETEC vaccine candidate, ETVAX®, has been developed to meet commercial requirements. We want to ensure that the new formulation gives rise to immune responses that are not inferior to the previous formulation of the vaccine that underwent earlier testing. This is done in a phase II double-blinded, […]

2021 03 01

R&D

Scandinavian Biopharma

The first children have been vaccinated in Scandinavian Biopharma’s large Phase IIb study in The Gambia

Scandinavian Biopharma announces that the first child has been vaccinated in The Gambia with the company’s ETEC vaccine candidate, ETVAX®. It is a randomised, placebo-controlled, and double-blind phase IIb study. The study will include about 5,000 children aged 6-23 months. The overall goal of the study is to investigate the protective effect against moderate to […]

2020 10 09

R&D

Scandinavian Biopharma

Scandinavian Biopharma enters into Agreement with USAMRAA to facilitate the development of the oral vaccine ETVAX® against travellers’ diarrhoea

25th of September 2020, Scandinavian Biopharma (SBH) entered into an Agreement with the United States Army Medical Research Acquisition Activity (USAMRAA) to support the production and development of the vaccine, with the long-term goal of preventing bacterial diarrhoea in war fighters. In April this year, SBH announced the promising preliminary findings from a Phase 2b […]

2020 09 01

R&D

Scandinavian Biopharma

We continue to expand and welcome Robert Lindberg

We are happy to announce that Robert Lindberg has joined our team. Robert recently graduate from Stockholm University in Degree of Master of Science with a Major in Molecular Biology. “It feels great to be a part of Scandinavian Biopharma. It’s really motivating to work with the development of a new vaccine that can contribute […]